Estrogen‐Induced LncRNA, LINC02568, Promotes Estrogen Receptor‐Positive Breast Cancer Development and Drug Resistance Through Both In Trans and In Cis Mechanisms

Endocrine therapy is the frontline treatment for estrogen receptor (ER) positive breast cancer patients. However, the primary and acquired resistance to endocrine therapy drugs remain as a major challenge in the clinic. Here, this work identifies an estrogen‐induced lncRNA, LINC02568, which is highl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xue, Ding, Jian‐cheng, Hu, Guo‐sheng, Shu, Xing‐yi, Liu, Yan, Du, Jun, Wen, Zi‐jing, Liu, Jun‐yi, Huang, Hai‐hua, Tang, Guo‐hui, Liu, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477896/
https://www.ncbi.nlm.nih.gov/pubmed/37404090
http://dx.doi.org/10.1002/advs.202206663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477896/
https://www.ncbi.nlm.nih.gov/pubmed/37404090
http://dx.doi.org/10.1002/advs.202206663

Ejemplares similares